Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • November 6, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6. Erratum for: Sci Rep. 2022 Sep 2;12(1):15013. PMID: 36333397; PMCID: PMC9636406.

Tags: General Internal Medicine, Publications

Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS)

Blanco LR, Hays RD. Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS). J Retire. 2024 Fall;12(2):76-94. doi: 10.3905/jor.2024.1.164. Epub 2024 Oct[...]

Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer

Schumm MA, Nikiforov YE, Nikiforova MN, Wald AI, Tseng CH, Smooke-Praw S, Wu JX, Yeh MW, Livhits MJ. Association of BRAF V600E allele frequency with[...]

Referrals and Black-White Coronary Heart Disease Treatment Disparities: A Qualitative Study of Primary Care Physician Perspectives

Qureshi N, Berry S, Damberg CL, Gibson B, Popescu I. Referrals and Black-White Coronary Heart Disease Treatment Disparities: A Qualitative Study of Primary Care Physician[...]